• LAST PRICE
    29.5700
  • TODAY'S CHANGE (%)
    Trending Up0.7300 (2.5312%)
  • Bid / Lots
    29.1200/ 1
  • Ask / Lots
    29.5500/ 1
  • Open / Previous Close
    28.8500 / 28.8400
  • Day Range
    Low 28.2000
    High 29.9535
  • 52 Week Range
    Low 8.8000
    High 44.7000
  • Volume
    31,541
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 28.84
TimeVolumeBLTE
09:32 ET105528.21
09:34 ET65028.5
09:36 ET199728.79
10:10 ET109928.69
10:17 ET262828.87
10:19 ET320829.3
10:21 ET249629.5
10:24 ET70029.3
10:26 ET65029.31
10:28 ET10029.3
10:30 ET39929.3
10:32 ET160029.2
10:33 ET80029.2
10:35 ET20029.21
10:39 ET10029.21
10:42 ET10029.2
10:44 ET40129.21
10:46 ET40029.21
11:11 ET40029.3
11:36 ET36829.3411
11:40 ET12529.6725
11:42 ET80029.49
11:56 ET30029.9
12:03 ET70029.545
12:05 ET35029.51
12:23 ET55529.5
01:50 ET28029.2
02:04 ET57229.1276
03:41 ET20029.76
03:43 ET116529.614
03:48 ET70229.5579
03:50 ET30029.57
03:56 ET35029.415
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBLTE
Belite Bio Inc
834.3M
-85.9x
---
United StatesACLX
Arcellx Inc
822.5M
0.0x
---
United StatesREPL
Replimune Group Inc
851.5M
-6.9x
---
United StatesVRDN
Viridian Therapeutics Inc
816.6M
-4.4x
---
United StatesAVXL
Anavex Life Sciences Corp
804.4M
-17.7x
---
United StatesPNT
POINT Biopharma Global Inc
804.1M
-9.3x
---
As of 2022-10-07

Company Information

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration (dry AMD) and autosomal recessive Stargardt disease (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. The Company is developing LBS-008 as an oral daily treatment for STGD1 and dry AMD. LBS-008 is a novel therapy targeting dry AMD and STGD1, which are untreatable conditions that cause progressive vision loss in affected individuals. LBS-008 is an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A (retinol) to the eye. The Company's LBS-009 is an anti- Retinol binding protein 4 (RBP4) oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

Contact Information

Headquarters
5820 Oberlin Drive, Suite 101, Suite 101SAN DIEGO, CA, United States 92121
Phone
858-246-6240
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Yu-Hsin Lin
Chief Financial Officer, Director
Hao-Yuan Chuang
Chief Scientific Officer
Nathan Mata
Vice President of Clinical Operations
Ching- Chen Chiu
Director
Hung- Wei Chen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$834.3M
Revenue (TTM)
$0.00
Shares Outstanding
24.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.34
Book Value
$0.69
P/E Ratio
-85.9x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.